Exploring FDA-Approved Treatment Options for Patients With Myelofibrosis
Andrew Kuykendall, MD, discusses the current treatment landscape for the patients with myelofibrosis and how this evolved over the last decade.
Andrew Kuykendall, MD, assistant member at the Moffitt Cancer Center, discusses the current treatment landscape for the patients with myelofibrosis (MF) and how this evolved over the last decade.
For a long time, Kuykendall says the only FDA-approved therapy for the treatment of patients with MF was ruxolitinib (Jakafi). Physicians relied on this therapy for almost a decade to treat disease-related symptoms and symptoms related to the spleen.
However, in August 2019, the FDA granted approval to fedratinib (Inrebic). Fedratinib is now available as treatment of patients with intermediate-2 or high-risk primary or secondary myelofibrosis, including post-polycythemia vera or post-essential thrombocythemia MF. Kuykendall says physicians have been waiting a long time for a new therapy to become approved in the setting of patients with MF.
<< For more on the FDA approval of fedratinib in myelofibrosis
FDA Approves Nilotinib With No Mealtime Restrictions in Ph-Positive CML
November 15th 2024The FDA has approved a re-engineered formulation of nilotinib with no mealtime restrictions for adult patients with newly diagnosed Ph-positive CP- and AP-CML, or for those resistant or intolerant to prior therapy, including imatinib.
Read More
